Genetic Architecture and Clinical Outcomes of Combined Lipid Disturbances.

coronary artery disease hypercholesterolemia hyperlipidemias hypertension hypertriglyceridemia

Journal

Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103

Informations de publication

Date de publication:
03 Jun 2024
Historique:
pubmed: 3 6 2024
medline: 3 6 2024
entrez: 3 6 2024
Statut: aheadofprint

Résumé

Dyslipoproteinemia often involves simultaneous derangements of multiple lipid traits. We aimed to evaluate the phenotypic and genetic characteristics of combined lipid disturbances in a general population-based cohort. Among UK Biobank participants without prevalent coronary artery disease, we used blood lipid and apolipoprotein B concentrations to ascribe individuals into 1 of 6 reproducible and mutually exclusive dyslipoproteinemia subtypes. Incident coronary artery disease risk was estimated for each subtype using Cox proportional hazards models. Phenome-wide analyses and genome-wide association studies were performed for each subtype, followed by in silico causal gene prioritization and heritability analyses. Additionally, the prevalence of disruptive variants in causal genes for Mendelian lipid disorders was assessed using whole-exome sequence data. Among 450 636 UK Biobank participants: 63 (0.01%) had chylomicronemia; 40 005 (8.9%) had hypercholesterolemia; 94 785 (21.0%) had combined hyperlipidemia; 13 998 (3.1%) had remnant hypercholesterolemia; 110 389 (24.5%) had hypertriglyceridemia; and 49 (0.01%) had mixed hypertriglyceridemia and hypercholesterolemia. Over a median (interquartile range) follow-up of 11.1 (10.4-11.8) years, incident coronary artery disease risk varied across subtypes, with combined hyperlipidemia exhibiting the largest hazard (hazard ratio, 1.92 [95% CI, 1.84-2.01]; Simultaneous assessment of multiple lipid derangements revealed nuanced differences in coronary artery disease risk and genetic architectures across dyslipoproteinemia subtypes. These findings highlight the importance of looking beyond single lipid traits to better understand combined lipid and lipoprotein phenotypes and implications for disease risk.

Sections du résumé

BACKGROUND UNASSIGNED
Dyslipoproteinemia often involves simultaneous derangements of multiple lipid traits. We aimed to evaluate the phenotypic and genetic characteristics of combined lipid disturbances in a general population-based cohort.
METHODS UNASSIGNED
Among UK Biobank participants without prevalent coronary artery disease, we used blood lipid and apolipoprotein B concentrations to ascribe individuals into 1 of 6 reproducible and mutually exclusive dyslipoproteinemia subtypes. Incident coronary artery disease risk was estimated for each subtype using Cox proportional hazards models. Phenome-wide analyses and genome-wide association studies were performed for each subtype, followed by in silico causal gene prioritization and heritability analyses. Additionally, the prevalence of disruptive variants in causal genes for Mendelian lipid disorders was assessed using whole-exome sequence data.
RESULTS UNASSIGNED
Among 450 636 UK Biobank participants: 63 (0.01%) had chylomicronemia; 40 005 (8.9%) had hypercholesterolemia; 94 785 (21.0%) had combined hyperlipidemia; 13 998 (3.1%) had remnant hypercholesterolemia; 110 389 (24.5%) had hypertriglyceridemia; and 49 (0.01%) had mixed hypertriglyceridemia and hypercholesterolemia. Over a median (interquartile range) follow-up of 11.1 (10.4-11.8) years, incident coronary artery disease risk varied across subtypes, with combined hyperlipidemia exhibiting the largest hazard (hazard ratio, 1.92 [95% CI, 1.84-2.01];
CONCLUSIONS UNASSIGNED
Simultaneous assessment of multiple lipid derangements revealed nuanced differences in coronary artery disease risk and genetic architectures across dyslipoproteinemia subtypes. These findings highlight the importance of looking beyond single lipid traits to better understand combined lipid and lipoprotein phenotypes and implications for disease risk.

Identifiants

pubmed: 38828614
doi: 10.1161/CIRCRESAHA.123.323973
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Thomas Gilliland (T)

Cardiovascular Research Center, Massachusetts General Hospital, Boston. (T.G., M.S.S., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.G., J.S.D., M.S.S., M.T., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Department of Medicine, Harvard Medical School, Boston, MA (T.G., M.S.S., K.P., S.M.U., M.C.H., P.N.).

Jacqueline S Dron (JS)

Center for Genomic Medicine, Massachusetts General Hospital, Boston. (J.S.D., P.N.).
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.G., J.S.D., M.S.S., M.T., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).

Margaret Sunitha Selvaraj (MS)

Cardiovascular Research Center, Massachusetts General Hospital, Boston. (T.G., M.S.S., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.G., J.S.D., M.S.S., M.T., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Department of Medicine, Harvard Medical School, Boston, MA (T.G., M.S.S., K.P., S.M.U., M.C.H., P.N.).

Mark Trinder (M)

Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.G., J.S.D., M.S.S., M.T., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC (M.T.).

Kaavya Paruchuri (K)

Cardiovascular Research Center, Massachusetts General Hospital, Boston. (T.G., M.S.S., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.G., J.S.D., M.S.S., M.T., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Department of Medicine, Harvard Medical School, Boston, MA (T.G., M.S.S., K.P., S.M.U., M.C.H., P.N.).

Sarah M Urbut (SM)

Cardiovascular Research Center, Massachusetts General Hospital, Boston. (T.G., M.S.S., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.G., J.S.D., M.S.S., M.T., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Department of Medicine, Harvard Medical School, Boston, MA (T.G., M.S.S., K.P., S.M.U., M.C.H., P.N.).

Sara Haidermota (S)

Cardiovascular Research Center, Massachusetts General Hospital, Boston. (T.G., M.S.S., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.G., J.S.D., M.S.S., M.T., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).

Rachel Bernardo (R)

Cardiovascular Research Center, Massachusetts General Hospital, Boston. (T.G., M.S.S., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.G., J.S.D., M.S.S., M.T., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).

Md Mesbah Uddin (MM)

Cardiovascular Research Center, Massachusetts General Hospital, Boston. (T.G., M.S.S., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.G., J.S.D., M.S.S., M.T., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).

Michael C Honigberg (MC)

Cardiovascular Research Center, Massachusetts General Hospital, Boston. (T.G., M.S.S., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.G., J.S.D., M.S.S., M.T., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Department of Medicine, Harvard Medical School, Boston, MA (T.G., M.S.S., K.P., S.M.U., M.C.H., P.N.).

Gina M Peloso (GM)

Department of Biostatistics, Boston University School of Public Health, Boston, MA (G.M.P.).

Pradeep Natarajan (P)

Cardiovascular Research Center, Massachusetts General Hospital, Boston. (T.G., M.S.S., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Center for Genomic Medicine, Massachusetts General Hospital, Boston. (J.S.D., P.N.).
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA (T.G., J.S.D., M.S.S., M.T., K.P., S.M.U., S.H., R.B., M.M.U., M.C.H., P.N.).
Department of Medicine, Harvard Medical School, Boston, MA (T.G., M.S.S., K.P., S.M.U., M.C.H., P.N.).

Classifications MeSH